Therapeutics Development Initiative 2009 Pre-Proposal Receipt Date: January 20, 2009 – 6:00pm US ETThe Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces the launch of its Therapeutics Development Initiative (TDI) for Spring 2009, a funding mechanism to support and stimulate preclinical Parkinson’s disease research at for-profit institutions. This funding program seeks to support preclinical development of Parkinson’s disease therapies which have the potential for fundamentally altering disease course and/or improving treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical preclinical studies necessary for developing, optimizing and evaluating therapeutic strategies that if successful can move into human testing. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the principal investigator who must be an employee of a for-profit entity. Academic investigators may have an advisory role in the project, but the operational and strategic ownership of the project must reside within the company. Investigators may seek up to two years of funding for preclinical development and testing of novel therapeutic approaches for the treatment or prevention of Parkinson’s disease. Please note that pre-proposals are mandatory and will be used to evaluate your proposal’s fit with the stated aims and review criteria of the RFP. All pre-proposals received in response to this program will be subjected to a triage process and only those pre-proposals deemed to be of suitable scientific merit will be invited to submit a full application. MJFF employs an expedited, abbreviated granting mechanism to accelerate discoveries and ultimately translate findings to PD patients more quickly. Conference Call MJFF will hold a 45 minute long conference call on December 16, 2008 at 12:00 PM U.S. Eastern Time to clarify and explain the Therapeutics Development Initiative 2009 program and to answer applicants' questions. To participate in this call, you must RSVP via email to conferencecalls@michaeljfox.org. Participants will receive a reply with call-in details.
While there are no restrictions as to the specific approaches to be studied under this RFP, successful applications are most likely to focus on at least one of the following categories: o Neuroprotective strategies focused on slowing or preventing the process of neuronal death. o Neuroregenerative strategies to restore or replace neuronal function. o Novel drug delivery mechanisms and/or surgical procedures. o Innovative therapeutic approaches to treat the motor and non-motor symptoms of PD, including cognitive dysfunction, autonomic dysfunction, sleep disorders, or depression among others. o Therapeutic approaches to alleviate complications of PD treatment including dyskinesias, etc.
If you would like to contact the Foundation, please call toll-free at 1-800-708-7644, or contact us by regular mail at the following address: The Michael J. Fox Foundation for Parkinson's Research Church Street Station P.O. Box 780 New York, NY 10008-0780
AACR Award for Outstanding Achievement in Cancer Research
Nominations for the 2009 Award will open in September 2008 Nomination deadline: 4:00 p.m. United States Eastern Standard Time on Wednesday, October 15, 2008. The Award & Lecture Through the generous contribution of an anonymous donor, the AACR established this Award in 1979 to give recognition to a young investigator on the basis of meritorious achievement in cancer research. In accordance with the wishes of the donor, the recipient must be no more than 40 years of age by the time the award is received. The winner of the 29th Annual AACR Award for Outstanding Achievement in Cancer Research will receive an honorarium of $5,000 and give a 50-minute lecture during the AACR 100th Annual Meeting in Denver, CO, USA (April 18-22, 2009.) Eligibility Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry, or government. The Award will be presented to an individual investigator. Institutions or organizations are not eligible for the Award. Candidates must not be more than 40 years of age by the time the Award is received. For the 2009 Award, a candidate's date of birth must be on or after April 18, 1968. Nomination Process Nominations may be made via letter from any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science. Candidates may not nominate themselves. Nomination letters must be sent electronically to the AACR by Wednesday, October 15, 2008 at 4:00 p.m., United States Eastern Time. Preferred file formats are *.doc, *.pdf. Your nomination is not considered fully submitted until you receive a confirmation e-mail from the AACR; confirmations will be sent within 2 business days The nomination letter must be addressed to the Selection Committee; be written in English; and not exceed 1,000 words. The content should include the following: the name of the AACR Award for which the candidate is being nominated; a brief statement of no more than 50-words summarizing the candidate's cancer research accomplishment(s) for which he or she is being nominated; a concise description of the candidate's outstanding cancer research accomplishments in the fields of epidemiology, biomarkers, and prevention, with the publications supporting these accomplishments directly referenced within the letter; and a concise description of the impact of these accomplishments on the field. Nominators are asked to maintain the confidentiality of the nomination process and to refrain from informing the candidate about the nomination. There is no restriction on the number of candidates that may be nominated by any individual scientist. There is no restriction on the number of nominators that may write nomination letters or that may sign a single nomination letter on behalf of a candidate. Selection Candidates for the Award will be considered by a prestigious international Selection Committee of renowned cancer leaders appointed by the President of the AACR. The Committee will consider all nominations as they have been submitted; the Committee may not combine submitted nominations, add a new candidate to a submitted nomination, or otherwise make alterations to the submitted nominations. After careful deliberations by the Committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and determination. Selection of the Award winner will be made on the basis of the candidate's meritorious achievements in cancer research. No regard will be given to race, gender, nationality, or religious or political view. Questions? Monique P. Eversley, Program Associate +1 (267) 646-0576; monique.eversley@aacr.org American Association for Cancer Research 17th Floor, 615 Chestnut Street Philadelphia, PA 19106-4404
AACR Princess Takamatsu Memorial Lectureship
The Lectureship The AACR Princess Takamatsu Memorial Lectureship was established and first presented in 2007 in honor of the late Princess Takamatsu of Japan. During her extraordinary life, Her Imperial Highness Princess Takamatsu expended tremendous efforts toward the public and humanitarian cause of the eradication of cancer. She is regarded as an honored and respected figure in Japan, the United States, and within the international cancer research community as a whole. This Lectureship will recognize an individual scientist whose novel and significant work has had or may have a far-reaching impact on the detection, diagnosis, treatment, or prevention of cancer, and who embodies the dedication of the Princess to multinational collaborations. The recipient of the 2nd Annual Lectureship will present a major, 50-minute lecture during the AACR Annual Meeting 2009 in Denver, CO, USA (April 18-22, 2009). The Lecturer will receive an unrestricted cash award of US$10,000, support to attend the AACR Annual Meeting, and a commemorative item serving as tangible witness to the singular honor of his/her selection. Eligibility Criteria Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry, or government. The Lectureship will be presented to an individual investigator. Institutions or organizations are not eligible for the Lectureship. Nomination Process Nominations for the Lectureship must be submitted electronically to awards@aacr.org no later than 4:00 p.m. US Eastern Time on October 15, 2008. Paper nominations will not be accepted. Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science. Candidates may not nominate themselves. Nominators are asked to maintain the confidentiality of the nomination process and to refrain from informing the candidate about the nomination. There is no restriction on the number of candidates nominated by any institution or nominator. Nomination Materials The following materials must be sent electronically to the AACR as noted above. Preferred file formats are *.doc, *.pdf. Your nomination is not considered fully submitted until you receive a confirmation e-mail from the AACR; confirmations will be sent within 2 business days. 1) Letter of Recommendation. The letter of recommendation must: be addressed to the Selection Committee; be written in English; and not exceed 1,000 words; specify the AACR Lectureship for which the candidate is being nominated; and describe the candidate's novel and significant work in cancer research and dedication to multinational collaborations, with the publications supporting these accomplishments directly referenced within the letter. 2) Candidate's CV. The candidate's curriculum vitae in English, including a complete list of the candidate's publications. 3) Summary Statement. A statement of no more than 50 words summarizing the candidate's accomplishments for which he or she is being nominated. Selection Candidates will be considered by a Selection Committee of international cancer leaders appointed by the President of the AACR. Selection of the Lecturer will be made on the basis of the novel and significant work, its far-reaching impact on the detection, diagnosis, treatment, or prevention of cancer, and his or her embodiment of the dedication of the Princess to multinational collaborations. No regard will be given to age, race, gender, nationality, geographic location, or religious or political views. After careful deliberations by the Committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Supporter Generously supported by Princess Takamatsu Cancer Research Foundation (Japan). Questions? Monique P. Eversley, Program Associate +1 (267) 646-0576; monique.eversley@aacr.org American Association for Cancer Research 17th Floor, 615 Chestnut Street Philadelphia, PA 19106-4404
AACR G.H.A. Clowes Memorial Award
Nominations for the 2009 Award will open in September 2008. Nomination deadline: 4:00 p.m. United States Eastern Time on Wednesday, October 15, 2008 The Award & Lecture The AACR and Eli Lilly and Company established this Award in 1961 to honor Dr. G.H.A. Clowes, who was a founding member of the AACR and a research director of Eli Lilly. The Clowes Award recognizes an individual with outstanding recent accomplishments in basic cancer research. The winner of the 49th Annual AACR G.H.A. Clowes Memorial Award will receive a $10,000 honorarium and will give a 50-minute lecture during the AACR Annual Meeting 2009 in Denver, CO, U.S.A. (April 18-22, 2009). The winner will also speak at the Eli Lilly and Company headquarters in Indianapolis, Indiana at the invitation of the company later in 2009. Eligibility Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry, or government. The Award will be presented to an individual investigator. Institutions or organizations are not eligible for the Award. Nomination Process Nominations may be made via letter from any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science. Candidates may not nominate themselves. Nomination letters must be sent electronically to the AACR by Wednesday, October 15, 2008 at 4:00 p.m., United States Eastern Time. Preferred file formats are *.doc, *.pdf. Your nomination is not considered fully submitted until you receive a confirmation e-mail from the AACR; confirmations will be sent within 2 business days The nomination letter must be addressed to the Selection Committee; be written in English; and not exceed 1,000 words. The content should include the following: the name of the AACR Award for which the candidate is being nominated; a brief statement of no more than 50-words summarizing the candidate's cancer research accomplishment(s) for which he or she is being nominated; a concise description of the candidate's outstanding cancer research accomplishments in the fields of epidemiology, biomarkers, and prevention, with the publications supporting these accomplishments directly referenced within the letter; and a concise description of the impact of these accomplishments on the field. Nominators are asked to maintain the confidentiality of the nomination process and to refrain from informing the candidate about the nomination. There is no restriction on the number of candidates that may be nominated by any individual scientist. There is no restriction on the number of nominators that may write nomination letters or that may sign a single nomination letter on behalf of a candidate. Selection Candidates will be considered by a Committee of international cancer leaders appointed by the President of the AACR. After careful deliberations by the Award Committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Selection of the Award winner will be made on the basis of the candidate’s recent accomplishments in basic cancer research. No regard will be given to age, race, gender, nationality, geographic location, or religious or political views. Supporter Generously supported by Eli Lilly and Company. Questions? Monique P. Eversley, Program Associate monique.eversley@aacr.org American Association for Cancer Research 17th Floor, 615 Chestnut Street Philadelphia, PA 19106-4404
Marcel Loncin Research Prize The Marcel Loncin Research Prize, given every other year, was first awarded in 1994. It honors and provides research funding to an IFT member or nonmember scientist or engineer conducting basic chemistry/physics/engineering research applied to food processing and improvement of food quality. The award is sponsored by the Lomi Foundation Endowment Fund of the Institute of Food Technologists.Foundation. AWARD: $50,000 paid in two annual installments and a plaque DEADLINE: December 1, 2009PURPOSE: The prize, given every other year, was first awarded in 1994. To honor and provide research funding for an IFT-member or nonmember scientist or engineer conducting basic chemistry/physics/engineering research applied to food processing and improvement of food quality. Prize money is to be used by the recipient in directing and carrying out a proposed research project, and to allow a successful scientist to help a young scientist(s) to also become successful. ELIGIBILITY: The application must be submitted by an individual eligible to carry out the research; i.e., it is not to be a joint research proposal or a laboratory-manager proposal, although cooperative research is encouraged. The applicant may be from academia, industry, or government, and the organization must verify on the application that it will agree to allow the applicant to work on the proposed research. SPECIAL REQUIREMENTS: The application form must be accompanied by a 5-page grant proposal and a one-page biographical sketch. The proposal should include an introduction with specific objectives, a short critical review of the literature, and a description of the proposed methods. The research proposal must show potential cross-fertilization and cooperation among academia, the food industry, and government organizations where possible. A purely analytical chemistry proposal will not qualify. The recipient of the prize will be announced during the 2010 IFT Annual Meeting. At the 2011 Annual Meeting, the recipient will make an oral, informal progress report at a breakfast/luncheon meeting attended by the confidential research jury. At the 2011 Annual Meeting, the recipient must (1) review the results of his/her study at a breakfast/luncheon meeting attended by the confidential research jury and (2) make an oral presentation of the results of the study as part of the technical program. The recipient must submit an abstract for oral presentation and must make the presentation in person. If appropriate, a Division may sponsor the recipient as a plenary speaker for one of the technical sessions or symposia. RESTRICTIONS: The prize money may not be used exclusively and specifically for purchase of new equipment. Also, the prize money cannot be used for salary for the prize recipient but can be used in part for salary of support personnel or graduate students as long as their work is directly related to the research proposal. Only 10% of the prize may be used for travel expenses and then only for travel to the IFT Annual Meeting. The recipient must agree not to charge any overhead expenses against prize money.
Institute of Food Technologists 525 W. Van Buren, Ste. 1000 Chicago, IL 60607 Phone: 312.782.8424 Fax: 312.782.8348 Email: info@ift.org
1
